Durasphere Injectable Bulking Agent
Carbon Medical Technologies, Inc. · Decision date Mar 13, 2026
What did the FDA approve?
FDA records P980053/S021 as a supplement to PMA P980053, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Mar 13, 2026.
FDA approval order statement
a change to the syringe cap of the 1 mL Durasphere device configuration
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Mar 13, 2026
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P980053/S021
- Regulatory pathway
- PMA supplement
- Applicant
- Carbon Medical Technologies, Inc.
- Product code
- LNM
- Decision code
- APPR
- Decision date
- Mar 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE.
- Applicant
- Carbon Medical Technologies, Inc.
- Product code
- LNM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P980053/S021 received
Application receipt date recorded by FDA.
P980053/S021 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P980053. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LNM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bulkamid Urethral Bulking SystemP170023/S024 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jul 1, 2026 | FDA |
| Merz North America, Inc. | PMA supplement | Jun 26, 2026 | FDA | |
| Merz North America, Inc. | PMA supplement | May 14, 2026 | FDA | |
COAPTITE Injectable ImplantP040047/S081 | Merz North America, Inc. | PMA supplement | Mar 18, 2026 | FDA |
COAPTITEP040047/S080 | Merz North America, Inc. | PMA supplement | Jan 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Carbon Medical Technologies, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1290 Hammond Rd., St. Paul, MN, 55110
Sources and methodology
- Original FDA record: P980053/S021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


